XENE
Xenon Pharmaceuticals Inc. · Healthcare
Insiders bought $1.7M of Xenon Pharmaceuticals Inc. in the last 12 months
2 insiders bought on 1 day.
XENE over the last year
Largest buyers, last 12 months
XENE after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
47 insider filings since 2016, newest first
Thomas Patrick Kelly · Chief Financial Officer
Ian Mortimer · President and CEO
Christopher John Kenney · Chief Medical Officer
Steven Gannon · Director
Gary Patou · Director
Gillian Cannon · Director
Ian Mortimer · President and CEO
Ian Mortimer · President and CEO
Ian Mortimer · President and CEO
Ian Mortimer · President and CEO
Gary Patou · Director
Elizabeth A. Garofalo · Director
Sherrington Robin · EVP, Strategy, Innovation
Steven Gannon · Director
Gary Patou · Director
Gary Patou · Director
Dawn Svoronos · Director
Simon N. Pimstone · Director
Ian Mortimer · President and CEO
Simon N. Pimstone · Director
Gary Patou · Director
Sherry Aulin · CFO
Sherrington Robin · EVP, Strategy, Innovation
James R. Empfield · EVP, Drug Discovery
Simon N. Pimstone · Director
Sherrington Robin · EVP, Strategy, Innovation
James R. Empfield · EVP, Drug Discovery
Simon N. Pimstone · Director
Simon N. Pimstone · Director
Simon N. Pimstone · Director
Sherrington Robin · EVP, Strategy, Innovation
Frank A Holler · Director
Simon N. Pimstone · CEO
Simon N. Pimstone · CEO
Frank A Holler · Director
Frank A Holler · Director
Mohammad Azab · Director
Mohammad Azab · Director
Bvf Partners L P/il · 10% owner
Dawn Svoronos · Director
Ian Mortimer · CFO and COO
Michael R Hayden · Director
Steven Gannon · Director
Bvf Partners L P/il · 10% owner
Frank A Holler · Director
Frank A Holler · Director
Frank A Holler · Director
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.